We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...

New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, including phased data submission to support earlier ...

Abzena, a CDMO, said it has expanded its early- and late-phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, U.K., and San Diego, CA, development and ...

Slingshot Biosciences (“Slingshot”) today announced two additions to its TruCytes™ cell mimic product line designed to accelerate cell therapy and stem cell research, development, and manufacturing ...

HOUSTON, Dec. 3, 2025 /PRNewswire/ -- Avance Biosciences today announced the opening of its new Potency and Cell-Based Assay Center of Excellence, a purpose-built facility designed to expand and ...

Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

CHICAGO — For patients with advanced heart failure, an injection of autologous mononuclear cells into damaged myocardia missed the primary endpoint in the sham-controlled, randomized, blinded CardiAMP ...

As the premier wellness clinic in Dubai, AEON Clinic is bridging the gap between traditional aesthetics and advanced ...

CAMBRIDGE, England and SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, announced the expansion of their early and ...